
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
GB Sciences, Inc. and Catalent Pharma Solutions, a global provider of delivery technologies and development solutions, announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients for its Parkinson’s disease therapies.
Read the full release






